IRTC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRhythm Holdings (IRTC) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now rather than wait. The stock has some constructive fundamentals and favorable analyst coverage, but the technical setup is mixed, hedge funds have been selling aggressively, and options sentiment is not clearly bullish. Given the current pre-market price of 111.74, I would not call it an immediate buy; hold and wait for a cleaner entry.
Current pre-market price is 111.74, near the pivot at 109.819 and below resistance at 116.057. Momentum is improving because MACD histogram is 0.549 and expanding positively, but RSI_6 at 56.196 is only neutral, not overbought or strongly bullish. The larger trend remains bearish on moving averages, with SMA_200 > SMA_20 > SMA_5, which signals the stock is still below a clean long-term trend reversal. Near-term pattern data suggests limited upside immediately, with a 40% chance of -0.29% next day and -1.61% next week, though a modest +0.69% next month is possible.
Recent analyst commentary remains mostly positive, with multiple firms keeping Buy/Outperform ratings after a strong Q1 beat and raise. Truist, Needham, Baird, Oppenheimer, Citi, Canaccord, and BofA all maintained constructive views despite some target cuts. BTIG highlighted the finalized LCD as a positive because it removes uncertainty around Medicare coverage, which is a meaningful event-driven catalyst for the business. The company also reportedly delivered strong revenue and EBITDA performance, with solid demand and margin improvement.
There is no fresh news in the past week, so there is no new catalyst driving immediate upside. Hedge funds are selling, and the selling increased 281.11% over the last quarter, which is a clear negative signal for near-term institutional support. Several analysts lowered price targets recently, reflecting more cautious valuation assumptions. The stock also remains technically below a fully confirmed long-term uptrend.
No detailed latest-quarter financial statement was provided due to a data error, but analyst notes indicate the company delivered a strong Q1 with a revenue and EBITDA beat, broad-based strength across the business, and a bump to FY26 guidance. Based on the available commentary, the latest quarter appears to have shown solid growth trends, improving margins, and better-than-expected execution. The latest quarter season referenced is Q1 2026.
Wall Street is still broadly constructive on IRTC, with multiple Buy/Outperform/Overweight ratings intact. However, price targets have mostly come down recently: Canaccord to 152 from 180, BofA to 180 from 225, JPMorgan to 175 from 215, Evercore to 160 from 170, while Citi and Truist modestly raised or maintained targets. The pro view is that demand remains strong, margins are improving, and the LCD decision reduces uncertainty. The con view is that valuations have cooled, some targets were reset lower, and expectations may be normalizing after a strong run. Overall, pros still outweigh cons fundamentally, but the revised targets imply less immediate upside than before.
